Journal
DRUG DISCOVERY TODAY
Volume 23, Issue 11, Pages 1833-1847Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2018.06.014
Keywords
-
Categories
Funding
- Brazilian CNPq/FAPEG DCR [300508/2017-4]
- Sao Paulo Research Foundation (FAPESP) [16/00194-8, 2017/02353-9, 2016/13805-5, 2012/16525-2]
- FAPESP Visiting Researcher Program [2017/02353-9]
- CNPq
- L'Oreal-UNESCO-ABC Para Mulheres na Ciencia
- L'Oreal-UNESCO International Rising Talents Program
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [16/13805-5, 16/00194-8, 17/02353-9] Funding Source: FAPESP
Ask authors/readers for more resources
Despite the recent outbreak of Zika virus (ZIKV), there are still no approved treatments, and early-stage compounds are probably many years away from approval. A comprehensive A-Z review of the recent advances in ZIKV drug discovery efforts is presented, highlighting drug repositioning and computationally guided compounds, including discovered viral and host cell inhibitors. Promising ZIKV molecular targets are also described and discussed, as well as targets belonging to the host cell, as new opportunities for ZIKV drug discovery. All this knowledge is not only crucial to advancing the fight against the Zika virus and other flaviviruses but also helps us prepare for the next emerging virus outbreak to which we will have to respond.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available